Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD34+ selected bone marrow mononuclear cells is an autologous cell therapy developed by Columbia University for the treatment of end-stage congestive heart failure. The therapy involves the isolation of CD34+ hematopoietic stem cells from a patient's own bone marrow, which are then injected intramyocardially during the surgical implantation of a Left Ventricular Assist Device (LVAD). These cells are hypothesized to enhance myocardial recovery and promote neo-vascularization through the secretion of various growth factors and cytokines, potentially improving cardiac function and allowing for earlier removal of mechanical support or better outcomes while awaiting heart transplantation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CD34+ selected bone marrow mononuclear cells (Columbia University).